Literature DB >> 26288115

Claudin 1 promotes migration and increases sensitivity to tamoxifen and anticancer drugs in luminal-like human breast cancer cells MCF7.

Bowen Zhou1, Anne Blanchard1,2, Nan Wang2, Xiuli Ma1, Jihyun Han1, Ingo Schroedter1, Etienne Leygue3, Yvonne Myal1,2.   

Abstract

Downregulation of claudin 1, a critical tight junction protein, has been correlated with increased invasiveness in breast cancer. However, recent studies suggest that claudin 1 contributes to the progression of some molecular subtypes of breast cancer. In this study, claudin 1 promotes migration in luminal-like MCF7 human breast cancer cells and increases their sensitivity to tamoxifen, etoposide, and cisplatin. We also observed an inverse relationship between upregulation of claudin 1 and TGFβ. Collectively, our results suggest that claudin 1 has the potential to be used as a predictive marker for treatment efficacy for specific breast cancer patient subgroups.

Entities:  

Keywords:  Breast cancer; Claudin 1; Estrogen; MCF7; Migration; TGFβ; Tamoxifen

Mesh:

Substances:

Year:  2015        PMID: 26288115     DOI: 10.3109/07357907.2015.1060996

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  9 in total

1.  Metformin resistant MDA-MB-468 cells exhibit EMT-like phenotype and increased migration capacity.

Authors:  Sahika Cingir Koker; Banu Yalcin; Irem Dogan Turacli
Journal:  Mol Biol Rep       Date:  2022-03-30       Impact factor: 2.742

2.  Cytotoxicity and 1H NMR metabolomics analyses of microalgal extracts for synergistic application with Tamoxifen on breast cancer cells with reduced toxicity against Vero cells.

Authors:  Hanaa Ali Hussein; Murni Nur Islamiah Kassim; M Maulidiani; Faridah Abas; Mohd Azmuddin Abdullah
Journal:  Heliyon       Date:  2022-03-26

3.  Identification of genes and pathways associated with MDR in MCF-7/MDR breast cancer cells by RNA-seq analysis.

Authors:  Minlan Yang; Hairi Li; Yanru Li; Yang Ruan; Chengshi Quan
Journal:  Mol Med Rep       Date:  2018-03-07       Impact factor: 2.952

4.  Small breast epithelial mucin promotes the invasion and metastasis of breast cancer cells via promoting epithelial‑to‑mesenchymal transition.

Authors:  Qiu-Hua Li; Zhao-Zhe Liu; Ya-Νan Ge; Xing Liu; Xiao-Dong Xie; Zhen-Dong Zheng; Yue-Hai Ma; Bin Liu
Journal:  Oncol Rep       Date:  2020-06-09       Impact factor: 3.906

5.  Lycopene upregulates ZO-1 and downregulates claudin-1 through autophagy inhibition in the human cutaneous squamous cell carcinoma cell line COLO-16.

Authors:  Suyun Bi; Li Li; Heng Gu; Min Li; Song Xu; Wenbo Bu; Mengli Zhang; Zhihai Zhou; Xu Chen
Journal:  J Cancer       Date:  2019-01-01       Impact factor: 4.207

6.  Profiling the expression of pro-metastatic genes in association with the clinicopathological features of primary breast cancer.

Authors:  Seyed-Mohammad Mazloomi; Mitra Foroutan-Ghaznavi; Vahid Montazeri; Gholamreza Tavoosidana; Ashraf Fakhrjou; Hojjatollah Nozad-Charoudeh; Saeed Pirouzpanah
Journal:  Cancer Cell Int       Date:  2021-01-06       Impact factor: 5.722

Review 7.  Claudin 1 in Breast Cancer: New Insights.

Authors:  Bowen Zhou; Amanda Moodie; Anne A A Blanchard; Etienne Leygue; Yvonne Myal
Journal:  J Clin Med       Date:  2015-11-27       Impact factor: 4.241

8.  CLDN6 promotes chemoresistance through GSTP1 in human breast cancer.

Authors:  Minlan Yang; Yanru Li; Xiangfeng Shen; Yang Ruan; Yan Lu; Xiangshu Jin; Peiye Song; Yantong Guo; Xiaoli Zhang; Huinan Qu; Yijia Shao; Chengshi Quan
Journal:  J Exp Clin Cancer Res       Date:  2017-11-07

Review 9.  Claudin-1, A Double-Edged Sword in Cancer.

Authors:  Ajaz A Bhat; Najeeb Syed; Lubna Therachiyil; Sabah Nisar; Sheema Hashem; Muzafar A Macha; Santosh K Yadav; Roopesh Krishnankutty; Shanmugakonar Muralitharan; Hamda Al-Naemi; Puneet Bagga; Ravinder Reddy; Punita Dhawan; Anthony Akobeng; Shahab Uddin; Michael P Frenneaux; Wael El-Rifai; Mohammad Haris
Journal:  Int J Mol Sci       Date:  2020-01-15       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.